BDBM317021 US9617267, Compound P-2009::US9617267, Compound P-2010::US9617267, Compound P-2011::US9617267, Compound P-2014::US9617267, Compound P-2016

SMILES Fc1ccc(NS(=O)(=O)c2ccc(cc2)C(F)(F)F)c(F)c1C=O

InChI Key InChIKey=HTVNXRNBUKJLBE-UHFFFAOYSA-N

Data  33 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 33 hits for monomerid = 317021   

LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 100nMAssay Description:Assays for biochemical and cell based activity are known in the art, for example, as described in PCT publication WO 2007/002433, the disclosure of w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 5.00E+3nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 5.00E+3nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 7.50E+3nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 7.50E+3nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Plexxikon

US Patent
LigandPNGBDBM317021(US9617267, Compound P-2009 | US9617267, Compound P...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, whe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent